Impact of some antiviral drugs on health care utilization for patients with COVID-19: a systematic review and meta-analysis.

IF 4.2 2区 医学 Q1 INFECTIOUS DISEASES Expert Review of Anti-infective Therapy Pub Date : 2023-09-05 DOI:10.1080/14787210.2023.2254491
Bincai Wei, Ruhao Zhang, Huatang Zeng, Liqun Wu, Rongxin He, Junyao Zheng, Hao Xue, Jinlin Liu, Fengchao Liang, Bin Zhu
{"title":"Impact of some antiviral drugs on health care utilization for patients with COVID-19: a systematic review and meta-analysis.","authors":"Bincai Wei,&nbsp;Ruhao Zhang,&nbsp;Huatang Zeng,&nbsp;Liqun Wu,&nbsp;Rongxin He,&nbsp;Junyao Zheng,&nbsp;Hao Xue,&nbsp;Jinlin Liu,&nbsp;Fengchao Liang,&nbsp;Bin Zhu","doi":"10.1080/14787210.2023.2254491","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>We aimed to assess the impact of antiviral drugs (fluvoxamine,remdesivir, lopinavir/ritonavir (LPV/r), molnupiravir, andnirmatrelvir/ritonavir (NRV/r)) on health care utilization (HCU) inCOVID-19 patients. We summarized findings from randomized controlledtrials (RCTs) and observational studies.</p><p><strong>Methods: </strong>We systematically searched four medical databases (PubMed, Web of Science, Embase, Cochrane Library) for COVID-19 studies up to February 15, 2023. A comprehensive review, meta-analysis, sensitivity analysis, and subgroup analysis were conducted. Pooled effects with 95% confidence intervals (CIs) were calculated for antiviral drugs' impact on hospitalization, mechanical ventilation (MV), and intensive care unit (ICU) outcomes.</p><p><strong>Results: </strong>Our analysis included 34 studies (584,978 patients). Meta-analysisindicated potential benefits: remdesivir and molnupiravir potentiallyreduced MV risk, and NRV/r correlated with lower hospitalizationrates. However, LPV/r did not notably curb HCU. Remdesivir waspreferable for high-risk COVID-19 patients, while molnupiravir andNRV/r were recommended for those aged 60 and above.</p><p><strong>Conclusion: </strong>Remdesivir, molnupiravir, and NRV/r may reduce HCU during the COVID-19 pandemic. However, due to limited study details and significant heterogeneity in effect estimates, further precise evidence is crucial, especially concerning emerging variants.</p>","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-17"},"PeriodicalIF":4.2000,"publicationDate":"2023-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anti-infective Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14787210.2023.2254491","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: We aimed to assess the impact of antiviral drugs (fluvoxamine,remdesivir, lopinavir/ritonavir (LPV/r), molnupiravir, andnirmatrelvir/ritonavir (NRV/r)) on health care utilization (HCU) inCOVID-19 patients. We summarized findings from randomized controlledtrials (RCTs) and observational studies.

Methods: We systematically searched four medical databases (PubMed, Web of Science, Embase, Cochrane Library) for COVID-19 studies up to February 15, 2023. A comprehensive review, meta-analysis, sensitivity analysis, and subgroup analysis were conducted. Pooled effects with 95% confidence intervals (CIs) were calculated for antiviral drugs' impact on hospitalization, mechanical ventilation (MV), and intensive care unit (ICU) outcomes.

Results: Our analysis included 34 studies (584,978 patients). Meta-analysisindicated potential benefits: remdesivir and molnupiravir potentiallyreduced MV risk, and NRV/r correlated with lower hospitalizationrates. However, LPV/r did not notably curb HCU. Remdesivir waspreferable for high-risk COVID-19 patients, while molnupiravir andNRV/r were recommended for those aged 60 and above.

Conclusion: Remdesivir, molnupiravir, and NRV/r may reduce HCU during the COVID-19 pandemic. However, due to limited study details and significant heterogeneity in effect estimates, further precise evidence is crucial, especially concerning emerging variants.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
部分抗病毒药物对COVID-19患者医疗保健利用的影响:系统综述和荟萃分析
背景:我们旨在评估抗病毒药物(氟伏沙明、瑞德西韦、洛匹那韦/利托那韦(LPV/r)、莫努匹拉韦和尼马特利韦/利托那韦(NRV/r))对covid -19患者医疗保健利用(HCU)的影响。我们总结了随机对照试验(rct)和观察性研究的结果。方法:系统检索截至2023年2月15日的4个医学数据库(PubMed、Web of Science、Embase、Cochrane Library),检索COVID-19研究。进行综合评价、荟萃分析、敏感性分析和亚组分析。以95%置信区间(ci)计算抗病毒药物对住院、机械通气(MV)和重症监护病房(ICU)结局的综合效应。结果:我们的分析包括34项研究(584,978例患者)。荟萃分析显示了潜在的益处:remdesivir和molnupiravir可能降低MV风险,NRV/r与较低的住院率相关。然而,LPV/r并没有显著抑制HCU。高危COVID-19患者优先使用Remdesivir, 60岁及以上患者推荐使用molnupiravir和nrv /r。结论:Remdesivir、molnupiravir和NRV/r可降低COVID-19大流行期间的HCU。然而,由于有限的研究细节和效果估计的显著异质性,进一步的精确证据是至关重要的,特别是关于新出现的变异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.20
自引率
0.00%
发文量
66
审稿时长
4-8 weeks
期刊介绍: Expert Review of Anti-Infective Therapy (ISSN 1478-7210) provides expert reviews on therapeutics and diagnostics in the treatment of infectious disease. Coverage includes antibiotics, drug resistance, drug therapy, infectious disease medicine, antibacterial, antimicrobial, antifungal and antiviral approaches, and diagnostic tests.
期刊最新文献
Could the next "disease X" be a pandemic of virus-induced encephalitis? What should our first medical response be? The opportunities and challenges of epigenetic approaches to manage herpes simplex infections. Potential activity of nanomaterials to combat SARS-CoV-2 and mucormycosis ‎coinfection‎. Clinical effectiveness of oral antivirals for non-hospitalized adult COVID-19 patients aged 18-60 years. Is self-medication with antibiotics among the public a global concern: a mixed-methods systematic review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1